bluuebunny/crossref_metadata_2025_split huggingface dataset:
Long‐term follow‐up of children born to mothers with acute leukemia during pregnancy
Authors: Avilés Agustin , Niz José 
Published: February 2007

AbstractSeventeen children born to mothers with acute leukemia who received chemotherapy during pregnancy were examined for physical health, growth, and development. The hematologic and neurologic status and school performance were also evaluated. Chromosomal studies were done in the long‐term survivors ranging in age from 4 to 22 years. The children had thorough history and physical examinations to detect any abnormal symptoms or signs. The mothers' previous treatment was documented. In each child growth and development, school performance, intelligence testing, neurologic examination, and hematologic evaluation including bone marrow were normal. Bone marrow cytogenetic studies were also normal. Chemotherapy was given during the pregnancy in each case, including 11 cases during the first trimester. No fetal malformations were found and no late side effects could be demonstrated. The results of this study indicate that pregnancy is not a counterindication for treatment of patients with acute leukemia, and in the cases described here chemotherapy is not associated with excessive risk to the fetus.
Epidemiological features of Wilms' tumor: Results of studies by the international society of paediatric oncology (SIOP)
Authors: Pastore Guido , Carli Modesto , Lemerle Jean , Tournade Marie F. , Voute Paul A. , Rey Annie , Burgers J. Marion V. , Zucker Jean M. , Burger Dietrich , De Kraker Jan , Delemarre Jan F. M. 
Published: February 2007

AbstractThis descriptive epidemiology study of 1,040 children with Wilms' tumor (WT) registered in the International Society of Paediatric Oncology (SIOP) clinical trials confirms the findings reported by the National Wilms' Tumor Study. The male:female rate was 0.89:1. The mean age at diagnosis of the 43 bilateral cases was significantly younger than children with unilateral renal involvement (32.4 vs 45 months). However, the mean ages at diagnosis for unilateral multicentric and for unicen‐tric WT were very similar. On the other hand, the mean age at diagnosis of children with sporadic aniridia and hypospadias was younger than the mean age of patients with or without other congenital malformations. Thus aniridia as well as hypospadias could be indices of the first mutation, according to the Knudson and Strong hypothesis. WT was reported in two members of each of five families. However, these familial cases were comparable in terms of demographic and clinical features to the nonfamilial ones. These data suggest that the heritable fraction of WT is relatively small and that genetic and environmental factors interact in the development of WT.
Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy
Authors: Pui Ching‐Hon , Bowman W. Paul , Ochs Judith , Dodge Richard K. , Rivera Gaston K. 
Published: February 2007

AbstractCyclic combination chemotherapy was administered to 26 patients with acute lymphoblastic leukemia who had relapsed in the bone marrow ≥ 6 months after elective cessation of therapy. Each patient had been in initial continuous complete remission for 36‐111 months (median, 47 months). Prednisone, vincristine, and doxorubicin induced second complete remissions in all patients within 1 month. Continuation therapy consisted of alternating 6‐week courses of 6‐mercaptopurine/methotrexate and vincristine/cyclo‐phosphamide with intervening reinforcement courses of prednisone/doxorubicin, for a total of 18 months. All patients received 4 weeks of late intensification therapy with the same agents used for remission reinduction. Periodic intrathecal methotrexate was given as reprophylaxis for subclinical central nervous system leukemia. The estimated rate of continuous failure‐free survival at 5 years is 31% ± 17% (2 SE). Eight patients remain free of leukemia for 42+ to 65+ months after completing therapy a second time. Adverse second events included 11 hematologic, 1 testicular, and 3 meningeal relapses. Patients who relapsed at more than 12 months after the completion of initial treatment have had significantly longer second remissions than patients whose first remissions were shorter (p = .04). None of the other six factors we analyzed showed predictive strength. These end results indicate that intensive cyclic continuation chemotherapy, as described here, will secure durable second remissions in approximately one‐third of the children with late bone marrow relapses.
Phase II study of recombinant beta interferon in patients with advanced non‐small‐cell lung carcinoma
Authors: Ettinger David S. , Harwood Kerry 
Published: February 2007

AbstractEighteen patients with advanced non‐small‐cell lung cancer (NSCLC) received recombinant beta interferon, 90 million units three times weekly. No complete or partial responses were seen. Five patients had stable disease for several months. Most patients experienced some toxicity, most commonly fever and chills. No dose reduction of interferon had to be made due to toxicity. Tachyphylaxis to symptoms of fever and chills occurred in most patients. While 33% of patients developed beta‐interferon‐binding antibodies, the incidence of interferon‐neutralizing activity was 0%. This dose and schedule of beta interferon did not result in significant anti‐tumor effects in advanced NSCLC. Stabilization of disease for up to 9 months in patients with previously progressive disease was of interest. Tachyphylaxis of symptoms should allow for dose escalation within patients. A dose‐escalating study has been initiated to evaluate the efficacy of beta interferon when given at each patient's maximally tolerated dose.
Referral of pediatric oncology patients for marrow transplantation and the process of informed consent
Authors: Chauvenet Allen R. , Smith Nancy M. 
Published: February 2007

AbstractA survey of 24 pediatric oncologists from 21 institutions not performing bone marrow transplants found that 156 patients were referred for transplants in the years 1984/85; only 10 of these patients were not transplanted. No patient in good clinical condition whose disease was under control was denied transplantation after evaluation at a transplant center. The decision for transplantation was made by the families and the referring pediatric oncologists, almost always before the patient was seen at a transplant center. The fact that almost all patient and family evaluations at transplant centers take place after a family has decided to have a marrow transplant has obvious implications regarding informed consent. Referring pediatric oncologists must attempt to provide the best possible information to families when decisions regarding marrow transplantation are actually being made.
Trends in the incidence of childhood and adolescent cancer in connecticut, 1935–1979
Authors: Van Hoff Jack , Schymura Maria J. , McCrea Curnen Mary G. 
Published: February 2007

AbstractTrends in the incidence of childhood cancer in Connecticut are reported and analyzed for the period 1935‐1979 by 5‐year age groups (0–4, 5–9, 10–14, 15–19 years), using a log linear model method. A threefold increase (P < .001) in the incidence of ALL in males 0–4 years of age was observed, with significant increases of smaller magnitude seen in males aged 5–9 and 15–19 and females aged 0–4 and 5–9. The incidence of central nervous system cancers also increased in several age groups for both sexes with the largest increase seen in males 0–4 years old. Significant increases in incidence of large magnitude were also observed for Hodgkin's disease, in males aged 15–19 years and females aged 10–19 years, for neuroblastoma in both sexes at ages 0–4 years, and for testis and ovarian cancer at ages 15–19 years. This study of trends in incidence of childhood cancers by 5‐year age groups has revealed significant changes, which would not have been as apparent if broader age groups had been used. These results provide relevant data for investigating the etiology of cancer during infancy, childhood, and adolescence. Trends in Connecticut are compared with findings from other registries in the United States and other countries.
Cytogenetic evidence for involvement of erythroid and granulocyte/macrophage progenitors in an infant with monosomy 7 syndrome presenting de novo
Authors: Tachibana N. , Raimondi S. C. , Santana V. M. , Dow L. W. 
Published: February 2007

AbstractMonosomy 7 presenting as a myelodysplastic syndrome following radiation and chemotherapy has been reported to involve a stem cell capable of both erythroid and granulocyte/macrophage differentiation. To determine if monosomy 7 presenting de novo also involves a multipotential stem cell, we examined mitoses from individual colony‐forming units (CFU)‐CM and burst‐forming units (BFU)‐E colonies derived from semisolid cultures of marrow from an infant with this disorder. Direct cytogenetic analysis of bone marrow cells disclosed the characteristic 45,XY,‐7 karyo‐type in 32 of 35 abnormal metaphases.Metaphases were obtained from 63 (73%) of 85 CFU‐GM and BFU‐E colonies (median metaphases per colony = 4, range = 1–21), with well‐banded analyzable chromosome spreads available for 15 of the colonies with metaphases. The monosomy 7 karyotype was present in all 14 metaphases from ten BFU‐E colonies and in all seven metaphases from five CFU‐GM colonies. These results indicate that the monosomy 7 karyotype can originate in haematopoietic stem cells with both erythroid and granulocyte/macrophage differentiative potential.
Phase II trial of ifosfamide and mesna in previously treated patients with non‐Hodgkin's lymphoma: Cancer and leukemia group B study 8552
Authors: Case Delvyn C. , Anderson James , Ervin Thomas J. , Gottlieb Arlan 
Published: February 2007

AbstractIfosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and 7 PR) with a median duration of response of 2.5 months. Myelosuppression was dose‐limiting. Hemorrhagic cystitis was observed in three patients (10%). Nausea and vomiting was generally mild or moderate. One patient developed transient neurotoxic symptoms with confusion and disorientation. An additional patient developed an anaphylactic‐type reaction with shortness of breath and respiratory strider during the fourth course of therapy. Ifosfamide, as a single agent, produces remissions of limited duration in non‐Hodgkin's lymphoma in patients in second or third relapse.
Minimal change disease as the etiology of the nephrotic syndrome in a patient with angioimmunoblastic lymphadenopathy
Authors: Staszewski Harry , Kumar Ganesh , Mishriki Yousri 
Published: February 2007

AbstractGlomerular lesions have rarely been reported with angioimmunoblastic lymphadenopathy (AILD). A patient with histologically documented AILD developed the nephrotic syndrome. Renal biopsy demonstrated minimal change disease. Both the lymphadenopathy and the nephrotic syndrome spontaneously remitted in this patient. Prior reports of renal disease in AILD and atypical lympho‐proliferative disorders are discussed. An association between the minimal change lesions and AILD is suggested.
Immunoblastic peripheral T‐cell lymphoma confined to bone marrow in an infant presenting with aspergillosis
Authors: Nuss Rachelle , Ribeiro Raul C. , Bunin Nancy , Behm Frederick , Jenkins Jesse , Berard Costan , Murphy Sharon B. 
Published: February 2007

AbstractA 16‐month‐old female infant presenting with pancytopenia and fever was found to have pulmonary aspergillosis and large‐cell immunoblastic non‐Hodgkin's lymphoma of peripheral post‐thymic origin isolated to bone marrow. Extensive noninvasive evaluations failed to demonstrate the disease in other extramedullary sites. The malignant cells were large and polymorphous; lacked terminal transferase; expressed surface CD‐2, CD‐3.CD‐8, and HLA‐DR antigens, and showed rearrangements of the T‐cell‐receptor β‐chain gene. To our knowledge, this type of lymphoma in an infant has not been reported before. Furthermore, aspergillosis is a rare presenting feature in patients with lymphoproliferative disease. In our case, it may reflect an underlying immune deficiency associated with the transformation and proliferation of a suppressor T cell.
Cytogenetic study of 130 childhood acute nonlymphocytic leukemias
Authors: Leverger Guy , Bernheim Alain , Daniel Marie‐Thérèse , Flandrin Georges , Schaison Gérard , Berger Roland 
Published: February 2007

AbstractCytogenetic studies performed on 130 consecutive childhood acute nonlymphocytic leukemias (ANLL) investigated in the same center between 1977 and 1986 are reported. The incidence of clonal chromosomal abnormalities was 68.5% with uneven distribution among the groups of the FAB nomenclature. The high incidence of t(8;21) translocation cases which was 58.6% of M2 ANLL cases was remarkable. Complete remission rate was lower (P<0.05) in ANLL with all karyotypically abnormal metaphases (AA) than in the other ANLL (NN with only normal metaphases and AN with a mixture of normal and abnormal metaphases). Median survival was also shorter in AA ANLL than in AN and NN cases (P<0.01). Median survival was different according to karyotype abnormalities: 11q anomalies and t(15;17) were not associated with a good prognosis and the t(8;21) is not associated with a particularly long median survival (16 months) when compared with other ANLL as opposed to the results of others. The longest survival (26 months) was observed in patients with acute myelomonocytic leukemia with bone marrow eosinophilia. It may be concluded that chromosome studies have a prognostic value in childhood ANLL.
Chemotherapy side effects in pediatric oncology patients: Drugs, age, and sex as risk factors
Authors: Lebaron Samuel , Zeltzer Lonnie K. , Lebaron Christine , Scott Shannon E. , Zeltzer Paul M. 
Published: February 2007

AbstractNausea, vomiting, and the extent to which chemotherapy‐bothered children were assessed by patient and parent ratings for 31 children (65 courses) receiving combination chemotherapy with either highdose cyclophosphamide or doxorubicin /daunorubicin. Patients and parents both reported more severe vomiting with cyclophosphamide than with the anthracyclines. The use of antiemetics did not affect emesis for the former drug; for the anthracyclines, there was more severe emesis for courses with antiemetics than for those with none. Adolescents reported more severe nausea than children, and females reported both more nausea and bother than males. There were no significant age or sex findings for parent reports. The findings suggest that chemotherapy‐related nausea and vomiting in children is a complex phenomenon not accounted for by drugs alone.
Phase II study of bisantrene administered by continuous 72‐hour infusion for advanced pancreatic adenocarcinoma
Authors: Marschke Robert F. , Kvols Larry K. , Cullinan Stephen A. , Laurie John A. , Mailliard James A. , Tschetter Loren K. , O'Connell Michael J. 
Published: February 2007

AbstractEighteen ambulatory patients who had proven metastatic adenocarcinoma of the pancreas and measurable disease but no previous chemotherapy were treated with bisantrene given by constant central intravenous infusion over 72 hours at a total dose of 300 mg/m2 repeated every 3 to 4 weeks. No objective regression was seen. The median interval to progression was 6 weeks; the median survival was 14 weeks. Primary toxic reactions were nausea, vomiting, and leukopenia. In no instance were these life‐threatening. When administered by the method we used, bisantrene cannot be recommended for treatment of advanced pancreatic adenocarcinoma.
Esophageal cancer in a young woman after treatment for osteosarcoma
Authors: Dewar J. M. , Courtney J. T. , Byrne M. J. , Joske R. A. 
Published: February 2007

AbstractFive years after completing adjuvant chemotherapy for osteosarcoma of the fibula, a 20‐year‐old woman developed an esophageal carcinoma. The association between prior chemotherapy and radiation exposure, and the significance of genetic factors and family history are discussed. This case exemplifies the importance of continued follow‐up of the long‐term survivors of tumor management.
Concurrent development of a thymic cyst and mediastinal Hodgkin's disease
Authors: Kaesberg Paul R. , Foley David B. , Pellett John , Hafez G. Reza , Ershler William B. 
Published: February 2007

AbstractA case is presented of a young adult female who presented with nodular sclerosing Hodgkin's disease and a mediastinal mass that proved to be a thymic cyst. Prior to this illness, a chest x‐ray had been ob tained that did not show a mediastinal mass. This case illustrates that thymic cysts may arise simultaneously with mediastinal Hodgkin's disease, rather than as a result of treatment or being present congenially.
Skin rash associated with Candida guilliermondii
Authors: Booth Linda V. , Collins Amanda L. , Lowes J. A. , Radford M. 
Published: February 2007

AbstractWe report a case in which the development of a skin rash in a neutropenic patient was associated with multiple blood culture isolates of Candida guilliermondii—an unusual isolate not previously documented to cause rashes.
Phase I/II study of bisantrene in childhood cancer: A report from the childrens cancer study group
Authors: Movassaghi Nasser , Krivit William A. , Krailo Mark D. , Hammond G. Denman 
Published: February 2007

AbstractA phase I/II study of bisantrene using a 3‐week schedule was undertaken in 171 children with refractory leukemias and solid tumors. The doses ranged from 190 to 430 mg/m2. The maximum tolerated dose for children with solid tumors and acute leukemias was 280 mg/m2 and 360 mg/m2 every 3 weeks, respectively. The dose limiting toxicities were hepatic and hematologic. One patient with ALL achieved a complete remission and partial responses were observed in three patients with soft‐tissue sarcomas. The data indicate that bisantrene, at the doses and schedule used in this study, has limited antitumor activity in pretreated children with Cancer.
I‐131 metaiodobenzylguanidine: Diagnostic use in neuroblastoma patients in relapse
Authors: Heyman Sydney , Evans Audrey E. , D'Angio Giulio J. 
Published: February 2007

AbstractMetaiodobenzylguanidine (MIBG) has been used for the detection and treatment of neuroectodermal tumors, including neuroblastoma. We report our experience with 131I‐MIBG used diagnostically in neuroblastoma patients with relapse. Thirty‐eight studies were performed in 26 patients. There were 24 children (range 3 months‐14 years) and two adults. While the study was found to be both sensitive and specific for the presence of disease, there are instances of discordance. False‐negative studies were found with a markedly anaplastic tumor and with two mature ganglioneuromas. A bone lesion was negative with 131I‐MIBG, but positive on bone scan. A biopsy confirmed the presence of neuroblastoma. Caution should be exercised when scanning pretreated patients, and perhaps with newly diagnosed patients as well.
Bone marrow biopsy in the initial staging of Hodgkin's disease
Authors: Doll Donald C. , Ringenberg Q. Scott , Anderson Sharon P. , Hewett John E. , Yarbro John W. 
Published: February 2007

AbstractResults of bone marrow biopsy were retrospectively evaluated in 120 previously untreated patients with Hodgkin's disease. The incidence of bone marrow involvement was 13%. All patients with marrow invasion had B symptoms and/or clinically advanced disease. When patients with bone marrow involvement were compared to those without there were significant differences in the incidence of B symptoms, the clinical stage, hemoglobin levels, leukocyte counts, platelet counts, and serum levels of lactate dehydrogenase and alkaline phosphatase. None of 59 patients with clinical stage IA and IIA had evidence of marrow invasion. This study demonstrates that trephine bone marrow biopsy is of value in detecting marrow involvement in specific subgroups of untreated patients with Hodgkin's disease, i.e., those patients with constitutional symptoms and/or clinical stage III or IV. However, bone marrow biopsy adds little to the initial staging of patients with clinical stage IA and IIA. Routine use of this procedure in such patients may be unnecessary.
Wide‐field radiation therapy plus simultaneous chemotherapy for refractory Hodgkin's disease
Authors: Gomez German A. , Krishnamsetty Ramachandra M. , Han Tin , Henderson Edward S. 
Published: February 2007

AbstractNine male patients with disseminated Hodgkin's disease who had relapsed and/or were refractory to two or more non‐“cross‐resistant” programs of combination chemotherapy (range, two to five previous programs; median, three) were admitted into a study of treatment with wide‐field low‐dose radiation therapy (2,000 cGy), to all lymph node bearing areas, the liver, the spleen, and in selected cases the lungs (1,000 cGy). Simultaneous with each course of radiation therapy, chemotherapy with BCNU and procarbazine given at 50% doses of a known program of chemotherapy (BOPP) with vincristine and prednisone was given.Treatment was completed in five patients. Three of these achieved a complete remission; the other two had a partial response. Of the other four, two died during treatment with interstitial pneumonitis (probably radiation induced), and two failed to respond. Remission durations were 18+, 38, and 44+ months. Pulmonary toxicity was severe; however, hematologic and other toxicities were acceptable. The incorporation of wide‐field low‐dose radiation should be considered in programs of rescue for patients with Hodgkin's disease who relapse or are refractory to standard combination chemotherapy.
Late relapses after treatment for acute lymphoblastic leukemia in childhood: A population‐based study from the nordic countries
Authors: Nygaard Randi , Moe Peter Johan , Brincker Hans , Clausen Niels , Nyman Ralf , Perkkiö Mikko , Eilertsen Mary Elizabeth , Johansen Ole Jakob , Väre Markus , Brinch Lorentz , Siimes Martti A. 
Published: February 2007

AbstractSeven late relapses of acute lymphoblastic leukemia occurring 5.5 to 12.3 years after cessation of therapy are reported in 986 patients who had discontinued treatment for leukemia acquired before the age of 15. The study covers patients from the five Nordic countries. Of the 434 patients with ALL who had passed 5 years of follow‐up without recurrence, seven have subsequently relapsed so far; an estimated cumulative proportion of 6.9% within the 10 years. In addition, we report a girl 15.9 years old at diagnosis who relapsed 7.3 years after cessation of therapy. These findings confirm that “cure” of acute lymphoblastic leukemia treated in the 1970s cannot be considered definite, even 5 years after discontinuation of therapy.
Combination chemotherapy for adrenal carcinoma: Response in a 5 1/2‐year‐old male
Authors: Crock Patricia A. , Clark A. C. L. 
Published: February 2007

AbstractAdrenocortical carcinoma is an uncommon tumor of childhood, and systematic studies of therapeutic options are not available. Children with very large tumours have a poor outlook with surgery alone, so that other treatment should be considered, but the literature is unhelpful in suggesting what this should be. In the case reported here, combination chemotherapy, including cisplatinum, gave a well‐documented good partial response, suggesting a possible role for adjuvant chemotherapy using such a drug combination.